Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Hsu

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Annals of the Rheumatic Diseases|December 18, 2013
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisJonathan Kay, Roy Fleischmann, Edward Keystone, et al.
Annals of the Rheumatic Diseases|September 1, 2017
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D studyTsutomu Takeuchi, Carter Thorne, George Karpouzas, et al.
Annals of the Rheumatic Diseases|November 13, 2014
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE studyAtul Deodhar, Jürgen Braun, Robert D Inman, et al.
Acta Biomaterialia|October 27, 2009
Biodegradable fibrous scaffolds with diverse properties by electrospinning candidates from a combinatorial macromer libraryRobert B Metter, Jamie L Ifkovits, Kevin Hou, et al.
Annals of the Rheumatic Diseases|May 14, 2013
Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotypePedro Machado, Robert Landewé, Jürgen Braun, et al.
The Journal of Rheumatology|April 17, 2014
The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trialDésirée van der Heijde, Atul Deodhar, Jürgen Braun, et al.
Annals of the Rheumatic Diseases|October 8, 2011
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitisDésirée van der Heijde, Pedro Machado, Jürgen Braun, et al.
Annals of the Rheumatic Diseases|November 1, 2011
Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumabCarrie Wagner, Sudha Visvanathan, Jürgen Braun, et al.
Arthritis Care & Research|July 12, 2012
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trialsElizabeth C Hsia, John J Cush, Eric L Matteson, et al.
Arthritis Research & Therapy|December 30, 2016
Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE studyRobert D Inman, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Annals of the Rheumatic Diseases|December 18, 2013
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisJonathan Kay, Roy Fleischmann, Edward Keystone, et al.
Annals of the Rheumatic Diseases|September 1, 2017
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D studyTsutomu Takeuchi, Carter Thorne, George Karpouzas, et al.
Annals of the Rheumatic Diseases|November 13, 2014
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE studyAtul Deodhar, Jürgen Braun, Robert D Inman, et al.
Acta Biomaterialia|October 27, 2009
Biodegradable fibrous scaffolds with diverse properties by electrospinning candidates from a combinatorial macromer libraryRobert B Metter, Jamie L Ifkovits, Kevin Hou, et al.
Annals of the Rheumatic Diseases|May 14, 2013
Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotypePedro Machado, Robert Landewé, Jürgen Braun, et al.
The Journal of Rheumatology|April 17, 2014
The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trialDésirée van der Heijde, Atul Deodhar, Jürgen Braun, et al.
Annals of the Rheumatic Diseases|October 8, 2011
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitisDésirée van der Heijde, Pedro Machado, Jürgen Braun, et al.
Annals of the Rheumatic Diseases|November 1, 2011
Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumabCarrie Wagner, Sudha Visvanathan, Jürgen Braun, et al.
Arthritis Care & Research|July 12, 2012
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trialsElizabeth C Hsia, John J Cush, Eric L Matteson, et al.
Arthritis Research & Therapy|December 30, 2016
Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE studyRobert D Inman, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Pageof 5